论文部分内容阅读
目的探讨米非司酮治疗围绝经期功能失调性子宫出血的临床疗效及安全性。方法 124例围绝经期功能失调性子宫出血患者作为研究对象,给予患者米非司酮进行治疗,监测患者入院时、服用米非司酮3个月后及6个月后的肝肾功能、激素水平、子宫内膜厚度、血常规等指标,比较其临床疗效。同时记录患者出现不良反应的情况。结果治疗6个月后患者卵泡刺激素(FSH)、促黄体生成素(LH)、睾酮(T)水平与入院时和治疗3个月时比较,差异无统计学意义(P>0.05),孕激素(P)、雌二醇(E_2)水平明显低于入院时和治疗3个月时,差异均有统计学意义(P<0.01);催乳素(PRL)水平低于入院时,差异具有统计学意义(P<0.05)。入院时子宫内膜厚度值为(1.8±0.5)cm,治疗3个月后为(0.9±0.4)cm,治疗6个月后为(0.8±0.3)cm;治疗6个月后子宫内膜厚度值小于入院时和治疗3个月时,差异有统计学意义(P<0.01)。入院时患者因围绝经期综合征也会出现乏力、眩晕、下腹痛、肛门坠胀感、恶心等症状,与治疗3个月和6个月后比较,差异无统计学意义(P>0.05)。结论米非司酮在围绝经期功能失调性子宫出血的临床治疗过程中相对安全可靠,能够起到有效调整月经周期的作用,使患者早日实现提前闭经,从而减轻患者的痛苦和心理负担,有利于患者重新回归工作和生活,可见米非司酮在围绝经期功能失调性子宫出血的临床应用中具有重要的治疗意义和价值。
Objective To investigate the clinical efficacy and safety of mifepristone in the treatment of dysfunctional uterine bleeding in perimenopausal period. Methods A total of 124 patients with dysfunctional uterine bleeding in the climacteric period were enrolled in this study. Mifepristone was given to patients for treatment. The patients were admitted to hospital for 3 months and 6 months after taking mifepristone, Level, endometrial thickness, blood and other indicators, to compare their clinical efficacy. At the same time record patients with adverse reactions. Results The levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (T) in patients at 6 months after treatment were not significantly different from those at admission and at 3 months of treatment (P> 0.05) The levels of P and E_2 were significantly lower than those at admission and at 3 months of treatment (P <0.01). The level of PRL was lower than that at admission Significance (P <0.05). The thickness of endometrium on admission was (1.8 ± 0.5) cm, (0.9 ± 0.4) cm after 3 months of treatment and (0.8 ± 0.3) cm after 6 months of treatment. The thickness of endometrium The value was less than the admission and 3 months of treatment, the difference was statistically significant (P <0.01). There was no significant difference in symptoms of fatigue, dizziness, lower abdominal pain, anal dilatory, nausea and other symptoms during the period of 3 months and 6 months after admission in patients with perimenopausal syndrome (P> 0.05) . Conclusion Mifepristone is relatively safe and reliable in the clinical treatment of dysfunctional uterine bleeding in peri-menopausal period, which can play an effective role in regulating the menstrual cycle and enable patients to achieve early amenorrhea as soon as possible, thus alleviating the suffering and psychological burden of patients with Which will help patients return to work and life again, showing that mifepristone has important therapeutic significance and value in the clinical application of dysfunctional uterine bleeding in perimenopausal period.